|HUG project leader||Patrick Petignat, Rosa Catarino,|
|Department, division||Département de Gynécologie et Obstétrique / Département de Gynécologie et Obstétrique /|
|Project partner abroad||Kenfack Bruno, Pierre-Marie Tebeu, Adamo Bongoe|
|Department, division||Unité de Santé Reproductive / Département d'obstétrique et gynécologie / Département d'obstétrique et gynécologiec|
|Institution||Hopital de District Dschang / Hôpital du Centre Hospitalier Universitaire de Yaoundé / Hopital Regional Edea|
|email@example.com, firstname.lastname@example.org, email@example.com|
|Cervical cancer is a significant reproductive health problem and the leading cause of cancer death among women in sub-Saharan Africa. Human papillomavirus (HPV) rapid test offers the opportunity to prevent cervical cancer in a single visit. Our goal is to to assess the feasibility and safety to prevent cervical cancer using rapid HPV test.
Study site will be a geographically well-defined area in West Region Cameroon (Dschang) with an estimated population of 250,000 inhabitants. Eligible women, aged between 30 and 49, will be invited to perform a rapid HPV self-test (Xpert HPV). HPV-negative women will be reassured and counseled to repeat the test in 5 to 10 years. HPV-positive women will be invited for visual inspection with acetic acid and Lugol (VIA/VILI) and therapy if abnormal. Quality control will be assessed using (i) histology of abnormal results, and (ii) a set of digital photographs of the cervix. Sensitivity, specificity, positive predictive value and negative predictive value will be calculated for the VIA/VILI using histopathology as gold standard. The pictures of the cervix will be analyzed by specialists in Geneva, as part of a telemedicine project.
The availability of a rapid HPV self-test provides an unprecedented opportunity to develop a cervical cancer screening programme in a population with low or medium resources in a single-visit approach. The study will also determine the level of support which is needed to implement and maintain high-quality HPV-based cervical cancer detection.